CLINICAL TRIALS PROFILE FOR CLOMIPRAMINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for clomipramine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004310 ↗ | Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder | Unknown status | Stanford University | Phase 2 | 1999-10-01 | OBJECTIVES: I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI) followed by a 12-week course of maintenance therapy in patients with obsessive compulsive disorder. |
| NCT00004310 ↗ | Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder | Unknown status | National Center for Research Resources (NCRR) | Phase 2 | 1999-10-01 | OBJECTIVES: I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI) followed by a 12-week course of maintenance therapy in patients with obsessive compulsive disorder. |
| NCT00254735 ↗ | Quetiapine Augmentation in Severe Obsessive Compulsive Disorder | Completed | AstraZeneca | Phase 3 | 2002-04-01 | The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| NCT00466609 ↗ | Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment | Completed | Novartis | Phase 4 | 2007-05-01 | This will be a controlled, randomized, double-blind and double-dummy study on the treatment augmentation strategy for obsessive compulsive disorder patients non-respondent to first line pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the association of fluoxetine with clomipramine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for clomipramine hydrochloride
Condition Name
Clinical Trial Locations for clomipramine hydrochloride
Trials by Country
Clinical Trial Progress for clomipramine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for clomipramine hydrochloride
Sponsor Name
